Posted by SLS on January 30, 2018, at 8:23:44
In reply to Atomic structure study of SSRIs, posted by PeterMartin on January 29, 2018, at 13:16:09
This represents a great leap in progress in developing models of important molecules. However, I think it must be acknowledged that this is not an endorsement of developing drugs that are pure specific serotonin reuptake inhibitors that miss other critical membrane receptors and intracellular processes. Why would reboxetine and atomoxetine, selective NE reuptake inhibitors, not work as well as desipramine, a tricyclic selective NE reuptake inhibitor, in the treatment of depression? Why do some people respond to one SSRI and not another? So, it appears that serotonin reuptake inhibition is not sufficient to treat all cases of depression (sibutramine doesn't work). I imagine the authors will emphasize this at some point and describe developing molecules with multiple domains that are optimized for multiple sites of action. Of course, it might be that one can mix and match different "purified" drugs to customize which sites are to be manipulated for each individual.
Depression is probably the outcome of a heterogeneous array of physiological dysfunctions. If this is true, it might be necessary to develop an array of drugs to effectively treat it.
There is so much yet to discover and understand.
- ScottSome see things as they are and ask why.
I dream of things that never were and ask why not.- George Bernard Shaw
poster:SLS
thread:1096756
URL: http://www.dr-bob.org/babble/20161215/msgs/1096762.html